Cerus (CERS) Stock: Buy, Sell, or Hold?
CERS - Cerus Corp
$2.31
-0.08 (-3.35%)
▼
5d:
+2.21%
30d:
-11.15%
90d:
-21.16%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 02, 2026
9d
Get Alerted When CERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CERS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: CERS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: CERS is currently trading at $2.31, which is considered slightly low relative to its 30-day fair value range of $2.26 to $2.56. From a valuation perspective, the stock is trading at a discount (Forward PE: -462.0) compared to its historical average (76.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CERS is in a downtrend. Immediate support is located at $2.12, while resistance sits at $2.41. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: CERS scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.12 (+121.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CERS is in a downtrend. Immediate support is located at $2.12, while resistance sits at $2.41. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: CERS scores 84/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.12 (+121.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.26 -
$2.56
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (84/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 121.9% below Wall St target ($5.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- BULLISH: Bottoming setup score 84/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$2.26 -
$2.56
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.12
Resistance Level
$2.41
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-462.00
Wall Street Target
$5.13
(+121.9%)
Revenue Growth (YoY)
9.5%
Profit Margin
-3.1%
PE vs Historical
-462.0 vs 76.8
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 9:16 AM ET
Data refreshes hourly during market hours. Next update: 10:16 AM
Data refreshes hourly during market hours. Next update: 10:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
29 analysts |
$96 | 45 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$121 | 50 HOLD |
|
EW
Edwards Lifesciences Corp |
STRONG BUY
29 analysts |
$102 | 51 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 32 SELL |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$83 | 39 SELL |
